5mg Marbocyl P Tablet - per Tablet

Description

5mg Marbocyl Tablets for Cats & Dogs

Marbocyl P may only be supplied with a valid veterinary prescription issued by your vet. You should only purchase Marbocyl P if you have or are in the process of arranging such a prescription. See information bar for further details.  

Marbocyl P are beige brown spotted round tablets Three strengths are available. Marbocyl P 5 mg containing 5 mg marbofloxacin. For use in dogs and cats. Marbocyl P 20 mg containing 20 mg marbofloxacin.For use in dogs. Marbocyl P 80 mg containing 80 mg marbofloxacin. For use in dogs.

Marbocyl P Uses
In Dogs Marbocyl is indicated in the treatment of skin and soft tissue infections (skin fold pyoderma impetigo folliculitis furunculosis cellulitis) for the treatment of urinary tract infections associated or not with prostatitis and respiratory tract infections caused by susceptible strains of organisms. In Cats (Marbocyl P 5mg Tablet only) Marbocyl is indicated for the treatment of skin and soft tissue infections (wounds abscesses phlegmons) and upper respiratory tract infections caused by susceptible strains of organisms.

Marbocyl P Dosage and administration
For oral administration. The recommended dose rate is 2 mg/kg per day in a single daily administration. To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing. In dogs for the treatment of skin and soft tissue infections treatment duration is at least five days. Depending on the course of the disease it may be extended up to 40 days. In urinary tract infections treatment duration is at least 10 days. Depending on the course of the disease it may be extended up to 28 days. In respiratory infections treatment duration is at least 7 days and depending on the course of the disease may be extended up to 21 days. In cats for the treatment of skin and soft tissue infections treatment duration is 3-5 days. For upper respiratory infections treatment duration is 5 days.

Contra-indications warnings etc
Marbocyl P should not be used in dogs aged less than 12 months or less than 18 months for exceptionally large breeds of dogs such as Great Danes Briard Bernese Bouvier and Mastiffs with a longer growth period. Not recommended for use in cats aged less than 16 weeks. Not suitable for infections resulting from strict anaerobes yeast or fungi. Do not use Marbocyl P 20mg or Marbocyl P 80mg tablets in cats. For the treatment of this species the Marbocyl P 5mg tablet is available. Special precautions for use in animals The fluoroquinolones have been shown to induce erosion of articular cartilage in juvenile dogs and care should be taken to dose accurately especially in young animals. The fluoroquinolones are known for their potential neurological side effects; cautious use is recommended in dogs and cats diagnosed as suffering from epilepsy. A low urinary pH could have an inhibitory effect on the activity of marbofloxacin. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly or are expected to respond poorly to other classes of antimicrobials. Whenever possible use of fluoroquinolones should be based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease effectiveness of treatment with other quinolones due to the potential for cross resistance. Adverse reactions (frequency and seriousness) At the therapeutic recommended dosage no severe side effects are to be expected in cats and dogs. In particular no lesions of the articular joints were encountered in clinical studies at the recommended dose rate. Mild side effects such as vomiting softening of faeces modification of thirst or transient increase in activity may occasionally occur. These signs cease spontaneously after treatment and do not necessitate cessation of the treatment. Use during pregnancy and lactation Studies in pregnant rats and rabbits showed no side effects on pregnancy. However no specific studies have been carried out in pregnant cats and dogs. Interaction with other medicinal products and other forms of interaction Fluoroquinolones are known to interact with orally administered cations (Aluminium Calcium Magnesium Iron.) In such cases the bioavailability may be reduced. Overdose (symptoms emergency procedures antidotes) if necessary Overdosage may cause acute signs in the form of neurological disorders which should be treated symptomatically. Withdrawal period(s) Not applicable Operator warning People with known hypersensitivity to fluoroquinolones should avoid using this product. In case of accidental ingestion seek medical attention and show product label and/or package leaflet to the doctor. Wear gloves when handling or dividing tablets. Wash hands after use.   Pharmaceutical precautions No special precautions for storage. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Legal category
Marbocyl P is a POM-V (Pet Prescription Required)